Licenses, Asset Acquisitions and Contingent Consideration - Additional Information (Details) - License Agreement - USD ($)		1 Months Ended
	Oct. 02, 2017	Oct. 31, 2017	Sep. 30, 2022	Dec. 31, 2020
Pulmokine, Inc. | In Process Research And Development Seralutinib
Business Acquisition [Line Items]
Product license term (in years)	10 years
Upfront payment		$ 5,500,000
Milestones accrued			$ 0	$ 5,000,000
Pulmokine, Inc. | In Process Research And Development Seralutinib | Maximum
Business Acquisition [Line Items]
Development and regulatory milestone payments, payable	$ 58,000,000
Commercial milestone payments, payable	45,000,000
Sales milestone payments, payable	$ 190,000,000
Aerpio Pharmaceuticals, Inc. | In Process Research And Development G B Zero Zero Four
Business Acquisition [Line Items]
Milestones accrued			$ 0